The presence of IL-17A in colorectal cancer, hepatocellular carcinoma and NSCLC is generally associated with poor prognosis, whilst the presence of IL-17A in ovarian carcinoma and esophageal squamous cells carcinoma is associated with anti-tumor response [34,35]. Here, IL17A is linked to neoplasm.